Harmony Biosciences Holdings, Inc. | Small-cap | Healthcare
$34.19
0.00%
| Harmony Biosciences Stock Comparison:
Harmony Biosciences vs VertexHarmony Biosciences vs RegeneronHarmony Biosciences vs Ocular TherapeutixHarmony Biosciences vs Beam TherapeuticsHarmony Biosciences vs VericelHarmony Biosciences vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 184.7M
Gross Profit 152.7M 82.68%
Operating Income 56.2M 30.45%
Net Income 45.6M 24.66%
EPS (Diluted) $0.78

Balance Sheet Metrics

Total Assets 1.1B
Total Liabilities 335.0M
Shareholders Equity 720.5M
Debt to Equity 0.46

Cash Flow Metrics

Operating Cash Flow 36.4M
Free Cash Flow 33.9M

Revenue & Profitability Trend

Harmony Biosciences Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i714.7M582.0M437.9M305.4M159.7M
Cost of Goods Sold i156.8M121.2M83.5M55.5M27.7M
Gross Profit i557.9M460.8M354.4M249.9M132.0M
Gross Margin % i78.1%79.2%80.9%81.8%82.6%
Operating Expenses
Research & Development i145.8M76.1M70.9M30.4M19.4M
Selling, General & Administrative i221.3M192.7M163.3M132.0M95.6M
Other Operating Expenses i-----
Total Operating Expenses i367.1M268.8M234.2M162.4M115.0M
Operating Income i190.8M192.0M120.2M87.5M17.0M
Operating Margin % i26.7%33.0%27.4%28.7%10.6%
Non-Operating Items
Interest Income i18.5M14.7M3.1M224.0K-
Interest Expense i17.5M23.8M18.8M24.2M28.2M
Other Non-Operating Income-68.0K-9.6M169.0K-26.1M-25.7M
Pre-tax Income i191.8M173.4M104.7M37.4M-36.9M
Income Tax i46.3M44.5M-76.8M2.8M0
Effective Tax Rate % i24.1%25.7%-73.3%7.6%0.0%
Net Income i145.5M128.9M181.5M34.6M-36.9M
Net Margin % i20.4%22.1%41.4%11.3%-23.1%
Key Metrics
EBITDA i233.4M231.3M146.9M106.6M24.2M
EPS (Basic) i$2.56$2.17$3.07$0.60$-2.48
EPS (Diluted) i$2.51$2.13$2.97$0.58$-2.48
Basic Shares Outstanding i5688545559469648591731215753154025772419
Diluted Shares Outstanding i5688545559469648591731215753154025772419

Income Statement Trend

Harmony Biosciences Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i453.0M311.7M243.8M234.3M228.6M
Short-term Investments i14.2M41.8M79.3M0-
Accounts Receivable i83.0M74.1M54.7M34.8M22.2M
Inventory i7.2M5.4M4.3M4.4M3.8M
Other Current Assets8.1M5.5M8.8M3.2M1.3M
Total Current Assets i579.3M451.1M400.3M284.4M262.9M
Non-Current Assets
Property, Plant & Equipment i-----
Goodwill i113.3M137.1M161.0M143.9M162.3M
Intangible Assets i-137.1M161.0M143.9M162.3M
Long-term Investments-----
Other Non-Current Assets196.6M150.7M89.5M4.3M902.0K
Total Non-Current Assets i419.9M360.4M273.6M149.0M164.2M
Total Assets i999.2M811.4M673.9M433.4M427.1M
Liabilities
Current Liabilities
Accounts Payable i13.7M17.7M3.8M1.0M2.6M
Short-term Debt i16.2M15.0M2.0M2.0M-
Current Portion of Long-term Debt-----
Other Current Liabilities5.7M7.8M1.6M1.4M314.0K
Total Current Liabilities i175.1M163.8M78.9M53.8M134.5M
Non-Current Liabilities
Long-term Debt i163.0M178.6M189.6M190.0M194.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities1.9M2.1M2.5M3.2M1.1M
Total Non-Current Liabilities i165.0M180.7M192.1M193.2M195.4M
Total Liabilities i340.0M344.5M271.0M246.9M329.9M
Equity
Common Stock i1.0K1.0K1.0K1.0K1.0K
Retained Earnings i2.2M-143.3M-272.1M-453.6M-488.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i659.2M467.0M402.8M186.5M97.2M
Key Metrics
Total Debt i179.3M193.6M191.6M192.0M194.2M
Working Capital i404.2M287.3M321.4M230.7M128.4M

Balance Sheet Composition

Harmony Biosciences Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i145.5M128.9M181.5M34.6M-36.9M
Depreciation & Amortization i24.1M24.4M23.4M18.8M10.2M
Stock-Based Compensation i42.6M31.7M26.2M15.7M4.7M
Working Capital Changes i-4.3M-11.5M-17.1M-15.0M-23.5M
Operating Cash Flow i225.1M165.8M131.9M56.7M-40.6M
Investing Activities
Capital Expenditures i-1.2M-312.0K-172.0K-298.0K-2.0K
Acquisitions i-33.1M-37.0M00-
Investment Purchases i-105.3M-127.5M-110.7M0-
Investment Sales i98.5M118.3M9.1M0-
Investing Cash Flow i-67.5M-46.4M-101.8M-298.0K-2.0K
Financing Activities
Share Repurchases i0-100.0M00-167.0K
Dividends Paid i-----
Debt Issuance i0200.0M0200.0M200.0M
Debt Repayment i-15.0M-201.2M-2.0M-200.5M-120.6M
Financing Cash Flow i-17.5M-110.6M-2.0M-2.0M208.9M
Free Cash Flow i218.7M219.1M104.3M-1.7M-5.0M
Net Change in Cash i140.1M8.7M28.0M54.5M168.2M

Cash Flow Trend

Harmony Biosciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 13.13
Forward P/E 10.56
Price to Book 2.74
Price to Sales 2.65
PEG Ratio 10.56

Profitability Ratios

Profit Margin 20.50%
Operating Margin 30.45%
Return on Equity 24.71%
Return on Assets 12.81%

Financial Health

Current Ratio 3.67
Debt to Equity 24.63
Beta 0.84

Per Share Data

EPS (TTM) $2.62
Book Value per Share $12.55
Revenue per Share $13.06

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
hrmy2.0B13.132.7424.71%20.50%24.63
Vertex 121.3B32.827.0522.77%31.86%8.89
Regeneron 60.4B14.371.9815.34%31.37%9.04
Ocular Therapeutix 2.0B-7.40-57.19%91.17%28.66
Beam Therapeutics 1.9B-3.851.59-51.36%0.00%14.08
Vericel 1.9B262.326.042.59%2.85%32.74

Financial data is updated regularly. All figures are in the company's reporting currency.